Aesthetics

Alopecia

Atopic Dermatitis

Bullous Diseases

Cutaneous Melanoma

Dermoscopy

Eczema

Hedgehog Inhibitors

Hidradenitis Suppurativa

Phototherapy

Psoriasis

Join the leading experts as they go in-depth on some of the most important topics in dermatology. Hear invaluable insights on mechanism of disease, treatment options, and more for some of the most challenging dermatologic conditions.

large_dan-lefebvre-cVI8ViAhU04-unsplash.jpg

medium_dan-lefebvre-cVI8ViAhU04-unsplash.jpg

small_dan-lefebvre-cVI8ViAhU04-unsplash.jpg

thumbnail_dan-lefebvre-cVI8ViAhU04-unsplash.jpg

dan-lefebvre-cVI8ViAhU04-unsplash.jpg

large_Discourses in Dermatology logo.png

medium_Discourses in Dermatology logo.png

small_Discourses in Dermatology logo.png

thumbnail_Discourses in Dermatology logo.png

Discourses in Dermatology logo.png

Discourses in Dermatology

UCB Bimzelx November 2025

Part 1: Psoriasis and Mental Health: Understanding Depression and Suicidality Risk

This 4-part video series brings together leading dermatologists to explore the intersection of mental health and chronic skin disease, a connection that continues to gain recognition in both research and clinical practice. Across the series, experts examine how psychiatric comorbidities influence dermatologic outcomes, review data on the mental health impact of chronic inflammatory conditions, and discuss how dermatologists can thoughtfully address these concerns in patient care. &nbsp;Psoriasis and the psychiatric comorbidityIn Part 1, Mark Lebwohl, MD, is joined by Rick Fried, MD, PhD, both a dermatologist and a clinical psychologist, to examine the deep and often underappreciated mental health impact of psoriasis. They open with a reminder that multiple dermatologic diseases influence mental health, with psoriasis being among the most studied but far from the only condition with significant psychiatric burden.Dr Lebwohl also outlines 4 dermatologic therapies that carry warnings related to suicidality: brodalumab, isotretinoin, apremilast, and bimekizumab. He notes that concerns about these warnings can meaningfully impact prescribing behavior.The baseline mental health status of patients with psoriasisDr Fried highlights extensive evidence showing that patients with psoriasis have substantially elevated rates of depression, anxiety, suicidal ideation, and completed suicides. Importantly, he notes psoriasis itself is an independent risk factor for these outcomes.He explains that multiple studies show that when psoriasis improves, associated depression and suicidality often also improve, sometimes dramatically, suggesting that treatment of the skin disease can be a direct, positive intervention for a patient’s mental health.Dr Lebwohl reinforces this point with data from a large survey demonstrating that major depression occurs more frequently among people with psoriasis than in the general US population, illustrating the need for dermatologists to recognize and address this burden.When mental health improves with skin disease controlDrawing from his psychology practice, Dr Fried shares that patients with severe psoriasis who have a history of depression or suicidality often benefit the most from highly effective dermatologic treatment, despite clinicians’ hesitations to prescribe when these treatments carry suicidality warnings. These patients frequently experience relief not only from their skin symptoms but also from the social, emotional, family, and intimate impacts of the disease.By the time patients reach dermatology care, many have endured years of topical prescription and over-the-counter treatment failures. He finds that simply engaging with a clinician who demonstrates empathy and confidence in a treatment plan can be impactful for these patients.The dermatologist’s role: life-saving potential through effective treatmentDr Lebwohl stresses that dermatologists may be uniquely positioned to save lives by rapidly improving severe psoriasis with highly efficacious therapy, even if the medication carries a suicidality warning. He notes that FDA labeling reflects a requirement to list all potential events, not proven causation, and that withholding effective therapy due to fear of labeling language may harm patients who need rapid control the most.Dr Fried agrees, emphasizing transparency and informed consent alongside a broader perspective: while labels enumerate theoretical risks, they do not list the severe consequences of undertreatment, including worsening psychiatric burden.Both clinicians highlight that untreated psoriasis is associated with worsening systemic and psychiatric outcomes and that dermatologists should be motivated to act quickly and aggressively when indicated.Closing thoughtsThey conclude by reviewing data demonstrating that biologics across classes are associated with lower rates of suicidal ideation and completed suicides compared to untreated psoriasis and compared to the general population. Studies from the past 20 years consistently show that untreated psoriasis is associated with more than a doubling in suicidal ideation and an approximate 20% increase in completed suicides.Key takeaways<ul><li>Psoriasis independently increases the risk of depression, anxiety, suicidal ideation, and suicide</li><li>Effective treatment, especially biologic therapy, can meaningfully reduce psychiatric symptoms</li><li>Dermatologists play a critical role in addressing both physical disease and its mental health consequences</li><li>Suicidality warnings on dermatologic drugs reflect reporting requirements, not proven causality</li><li>Early, effective, empathetic intervention can improve quality of life across emotional, social, and physical domains</li></ul><a target="_blank" rel="noopener noreferrer" href="https://dermsquared.com/videos/discourses-in-dermatology">Click here</a> to view the other videos in the series.&nbsp;

Part 2: Psoriasis and Mental Health: The Inflammatory and Biochemical Pathways

This 4-part video series brings together leading dermatologists to explore the intersection of mental health and chronic skin disease, a connection that continues to gain recognition in both research and clinical practice. Across the series, experts examine how psychiatric comorbidities influence dermatologic outcomes, review data on the mental health impact of chronic inflammatory conditions, and discuss how dermatologists can thoughtfully address these concerns in patient care. &nbsp;The inflammation–depression connectionIn Part 2, Drs Lebwohl and Fried deepen their exploration by discussing the biochemical basis linking psoriasis and depression. Dr Lebwohl begins with an intriguing observation: bupropion, a well-known antidepressant, is also a TNF inhibitor, illustrating biochemical overlap between inflammatory pathways and mood regulation.Some inflammatory mediators elevated in psoriasis are also implicated in depression, suggesting a shared biological landscape beyond the psychosocial burden of visible skin disease.Is depression in psoriasis biologic, psychologic, or both?Dr Fried addresses a longstanding question: are psychiatric symptoms in psoriasis primarily due to disease burden, or are they driven by central biologic mechanisms?He emphasizes that the answer is unequivocally both. Inflammatory cytokines released from skin lesions enter the systemic circulation, cross the blood–brain barrier, and alter neurotransmitter uptake, affecting serotonin, norepinephrine, and dopamine. These changes directly contribute to mood symptoms.This dual mechanism reinforces that addressing inflammation can also address psychiatric symptoms.Future directions: neurotransmitter testing and combined therapiesDr Fried discusses emerging possibilities for objectively measuring neurotransmitters through blood, urine, or imaging strategies. If clinicians could quantify depletion in patients with inflammatory skin disease, they might feel more confident pairing SSRIs or SNRIs with biologics when needed.He highlights growing evidence that depression is, in part, an inflammatory disorder and that antidepressants themselves have anti-inflammatory effects, making them strong potential partners to biologic therapy.Examining suicidality concerns with bimekizumabThe conversation shifts to the suicidality warning for bimekizumab, one of the fastest and most effective psoriasis therapies available. Dr Lebwohl reviews a publication by Blauvelt et al that examined Phase 2 and 3 clinical trial data and found no increased risk of suicidality in patients treated with bimekizumab compared to the general population and compared to patients treated with other IL-17 or IL-23 inhibitors.Despite this, the warning remains on the label, and some clinicians avoid prescribing it. Dr Lebwohl cautions that this hesitancy may prevent high-need patients from accessing a highly effective treatment.Psychological improvement with effective therapyDr Lebwohl closes by sharing another notable trial finding: in pivotal trials, among patients receiving bimekizumab, 93% reported no or minimal depression, compared with 81% of placebo-treated patients. This reinforces that improving skin disease can significantly improve psychological well-being.Key takeaways<ul><li>Psoriasis and depression may share overlapping inflammatory pathways</li><li>Inflammatory cytokines can influence neurotransmitter activity and mood</li><li>Treating systemic inflammation can improve both skin and psychiatric symptoms</li><li>Clinical trial data show no increase in suicidality with bimekizumab compared with placebo, the general population, or other biologics</li></ul><a target="_blank" rel="noopener noreferrer" href="https://dermsquared.com/videos/discourses-in-dermatology">Click here</a> to view the other videos in the series.&nbsp;

Part 3: Psoriasis and Mental Health: How to Navigate SI/B Warnings With Patients

This 4-part video series brings together leading dermatologists to explore the intersection of mental health and chronic skin disease, a connection that continues to gain recognition in both research and clinical practice. Across the series, experts examine how psychiatric comorbidities influence dermatologic outcomes, review data on the mental health impact of chronic inflammatory conditions, and discuss how dermatologists can thoughtfully address these concerns in patient care. &nbsp;A practical framework for patient conversationsIn Part 3, Drs Lebwohl and Fried turn to the clinician–patient dialogue around therapies that carry suicidal ideation/behavior warnings (SI/B). Dr Lebwohl describes his efficient and effective approach, designed to give patients clarity without overwhelming them.He notes that many patients research their medications and inevitably encounter suicidality language. His strategy involves succinctly explaining that the FDA must list every reported event, even when trial data explicitly state there is no causal association. He then grounds the conversation in data; for example, highlighting that bimekizumab-treated patients demonstrated significantly better mental health outcomes than those on placebo.Reframing the risk: the cost of undertreatmentBoth clinicians emphasize that severe psoriasis itself is associated with increased depression, anxiety, suicidal ideation, and suicide. Effective treatment is a powerful tool for reversing these risks.Dr Lebwohl stresses that when patients are depressed, withholding high-efficacy therapies because of labeling language may cause greater harm. The act of rapidly improving their disease is often the first step toward improving their mental well-being.Communication style: clear, confident, and compassionateDr Fried reinforces the importance of clarity and empathy in these conversations. While shared decision-making is essential, many patients still look to their clinician for a straightforward recommendation.Both experts recommend a structured approach:<ol><li>Acknowledge the SI/B language</li><li>Explain the FDA’s reporting requirements</li><li>Clarify that available data show no causal relationship</li><li>Highlight that treating the inflammatory disease can improve mental health</li><li>Recommend the therapy you believe is best for the patient</li></ol>This entire process, Dr Lebwohl notes, takes about one minute in practice.Key takeaways<ul><li>Dermatologists should address SI/B language proactively and confidently with patients</li><li>FDA-required labeling reflects reported events, not causation</li><li>Effective psoriasis treatment reduces psychiatric symptoms and risk</li><li>Clear, compassionate communication strengthens trust and decision-making</li><li>Patients often benefit from direct guidance on the clinician’s recommendation</li></ul><a target="_blank" rel="noopener noreferrer" href="https://dermsquared.com/videos/discourses-in-dermatology">Click here</a> to view the other videos in the series.&nbsp;

A Review of Dermoscopy Techniques With Michelle Tarbox, MD

Leading With Intention in Aesthetic Assessment

Recognizing Bullous Pemphigoid Earlier in Clinical Practice

MD, PhD

Tildrakizumab in Psoriasis: Adherence, Persistence, and the Role of In-Office Administration

Advancing Bullous Pemphigoid Care: Clinical Insights From Dr. Del Rosso 

Strengthening Confidence in Hedgehog Inhibitors for Locally Advanced Basal Cell Carcinoma

Advancing Melanoma Prognostics: Clinical Evidence Supporting the 31-GEP Test

MD, FAAD

Topical Truths: Managing AD in the Real World

The Oral Conversation: How We Talk to Patients About Systemic Therapy Today

Shining the (RED) Light on Photobiomodulation

Part 4: How Dermatologists Approach SI/B Warnings in Daily Practice

Fall Clinical Continuity Experience - Vtama - Lecture Recap Video

Four Years of Data: Durability and Distinction with TYK2 Inhibition 

What an Oral Option Means for Psoriasis Care 

LAUNCH ALERT: FDA Approves Anzupgo (Delgocitinib) Cream for Moderate-to-Severe Chronic Hand Eczema in Adults

Bimzelx in Focus: Versatile Care for Enhanced Dermatologic Outcomes

Discover VTAMA: A Next-Generation Treatment for Plaque Psoriasis

VTAMA: A New Standard in Psoriasis Management

Exploring the MyPath Melanoma Test for Guiding Management and Care Decisions in Patients with Ambiguous Lesions 

MD, FAAD 

Bimekizumab for Plaque Psoriasis: Its Impact in Clinical Practice 

Bimekizumab for Plaque Psoriasis: Insights into Efficacy, Safety, and Dosing